Non-small cell lung cancer may be able to be treated by stereotactic ablative radiotherapy. A study published by The Lancet Oncology has shown that researchers conducted an analysis that shows promising results. Researchers do note that because of the small patient sample size and median follow-up being only 40.2 months, additional randomized studies comparing the two patients with operable NSCLC are needed. The article does state that “stereotactic ablative radiotherapy could be an option for treating patients with operable stage I NSCLC. SABR for inoperable stage I NSCLC has shown promising results, but two independent, randomised, phase 3 trials of SABR in patients with operable stage I NSCLC closed early due to slow accrual. We aimed to assess overall survival for SABR versus surgery by pooling data from these trials.”
To read more about the study and its results visit the website here.
